Phenytoin toxicity management
Reading File
Finding Sources
Finding Sources
Searching PubMed
phenytoin toxicity management
The primary source is Tintinalli's Emergency Medicine. Let me read the relevant sections.
Reading File
Excellent — I have a rich section. Let me read further to get the treatment section.
Reading File
I've drifted into carbamazepine. The phenytoin treatment section was at lines 2495–2530. Let me read it specifically.
Reading File
Reading File
I now have comprehensive content. Here is a structured overview of phenytoin toxicity management:
Phenytoin Toxicity — Management
Pharmacology Background
Phenytoin blocks voltage-sensitive, frequency-dependent sodium channels, suppressing repetitive neuronal activity. It is available orally and as an IV formulation — the parenteral vehicle contains 40% propylene glycol + 10% ethanol at pH 12, which is responsible for most cardiovascular toxicity seen with IV use.
Fosphenytoin is a prodrug (converted by phosphatases in ~10–15 min) that avoids the propylene glycol vehicle, is water-soluble, and can be given IM — but cardiovascular toxicity can still occur.
Clinical Features of Toxicity
CNS (most common, dose-related)
| Plasma Level (µg/mL) | Toxic Effects |
|---|---|
| < 10 | Usually none |
| 10–20 | Occasional mild nystagmus |
| 20–30 | Nystagmus |
| 30–40 | Ataxia, slurred speech, nausea/vomiting |
| 40–50 | Lethargy, confusion |
| > 50 | Coma, seizures |
Nystagmus is the earliest sign — first on forced lateral gaze, then spontaneous. Progression: sedation → lethargy → ataxia → dysarthria → confusion → coma → apnea.
Additional CNS: tremor, diplopia, ophthalmoplegia, choreoathetoid movements, hallucinations, encephalopathy.
Cardiovascular (IV administration only)
Cardiac toxicity after isolated oral overdose in a healthy patient has not been reported. IV toxicity is primarily due to the propylene glycol diluent:
- Hypotension (decreased peripheral vascular resistance)
- Bradycardia, AV nodal block (can progress to complete block)
- Ventricular tachycardia, ventricular fibrillation, asystole
- ECG changes: ↑PR interval, widened QRS, ST/T changes
- Higher risk in elderly, underlying cardiac disease, critically ill
Vascular/Soft Tissue (IV extravasation)
- Skin and soft tissue necrosis
- Compartment syndrome, limb gangrene
- "Purple glove syndrome": delayed bluish discoloration → erythema → edema → vesicles/bullae → tissue ischemia
Hypersensitivity (onset 1–6 weeks after starting therapy)
- Anticonvulsant hypersensitivity syndrome: eosinophilia, rash, pseudolymphoma, SLE, pancytopenia, hepatitis, pneumonitis
Other chronic toxicities
- Gingival hyperplasia, hirsutism, acne, coarsening of facial features
- Fetal hydantoin syndrome, hemorrhagic disease of newborn
- Stevens-Johnson syndrome
- Peripheral neuropathy, hyperglycemia/hypoglycemia
Diagnosis
- Therapeutic range: total phenytoin 10–20 µg/mL (40–80 µmol/L); free phenytoin 1–2 µg/mL
- Oral absorption is slow, variable, and erratic — peak typically 3–12 hours after a single dose; delayed further in overdose
- Serial levels are required — a single level cannot determine peak or guide discharge
- Hypoalbuminemia alters interpretation (phenytoin is ~90% protein-bound); use the Sheiner-Tozer correction or measure free phenytoin directly in patients with hypoalbuminemia or renal failure
Treatment
General (oral overdose)
- Airway, breathing, circulation — standard supportive care
- Correct acidosis (respiratory or metabolic) — acidosis increases the free (active) fraction of phenytoin
- Activated charcoal: Multidose activated charcoal (MDAC) may decrease drug half-life but does not decrease time to recovery or change outcome — consider if not obtunded and within a reasonable window
- Cardiac monitoring: Not necessary after isolated oral ingestion
- Seizures: Treat with IV benzodiazepines or phenobarbital (note: seizures are uncommon in phenytoin overdose)
- Severe/persistent toxicity: Hemodialysis and hemoperfusion can produce substantial improvement in neurologic toxicity
IV Infusion Toxicity
- Slow infusion rate is critical (≤50 mg/min in adults; ≤1 mg/kg/min in elderly/cardiac patients)
- Hypotension: Stop or slow infusion → isotonic crystalloid; usually responds promptly
- Bradycardia/heart block: Atropine; temporary cardiac pacing for symptomatic bradyrhythmias
- Fosphenytoin preferred over IV phenytoin for parenteral use (lower CV risk, no propylene glycol)
Hypersensitivity
- Discontinue phenytoin immediately
- Manage per the severity (corticosteroids, supportive care for SJS)
Disposition
| Scenario | Disposition |
|---|---|
| Serious complications (seizures, coma, significant AMS/ataxia) | Admit |
| Mild symptoms, declining levels, clinically improving | Observe in ED; discharge once levels declining and clinically well |
| Chronic intoxication — minimal signs, adequate home care, level declining | May discharge after 6–8 hours since last dose |
| Intentional overdose | Psychiatric evaluation before discharge |
Key principle: Phenytoin therapy should be stopped in all cases of toxicity. If toxicity resolves, levels may be reassessed in 2–3 days to guide resumption.
— Tintinalli's Emergency Medicine: A Comprehensive Study Guide, Chapter 197 (Anticonvulsants), pp. 1325–1326
This is a shared conversation. Sign in to Orris to start your own chat.